Abiopharma

BillionToOne is transforming healthcare by redefining molecular diagnostics. Our revolutionary single molecule NGS (smNGS) platform achieves what was once thought impossible - detecting and precisely quantifying genetic targets with single-molecule sensitivity. This superior technology platform has enabled us to build category-defining prenatal and oncology products. Our products reveal actionable insights from a simple blood draw that are fundamentally changing how diseases are diagnosed and treated, leading to a paradigm shift in personalized medicine. We believe our novel smNGS platform technologies, combined with our AI-enhanced integrated workflow, allow us to push the technology frontier forward and deliver on the full promise of non-invasive liquid biopsy.

Additional info from NASDAQ:
BillionToOne is transforming healthcare by redefining molecular diagnostics. Our revolutionary single molecule NGS (smNGS) platform achieves what was once thought impossible - detecting and precisely quantifying genetic targets with single-molecule sensitivity. This superior technology platform has enabled us to build category-defining prenatal and oncology products. Our products reveal actionable insights from a simple blood draw that are fundamentally changing how diseases are diagnosed and treated, leading to a paradigm shift in personalized medicine. We believe our novel smNGS platform technologies, combined with our AI-enhanced integrated workflow, allow us to push the technology frontier forward and deliver on the full promise of non-invasive liquid biopsy.